Funder
University of Kentucky College of Pharmacy
Reference68 articles.
1. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes;Kim;Nat Prod Rep,2013
2. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma;Stewart;N Engl J Med,2015
3. Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents;Kurtin;J Adv Pract Oncol,2013
4. Next-generation proteasome inhibitors for cancer therapy;Park;Transl Res,2018
5. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma;Kuhn;Blood,2007
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献